Xencor Inc

XE9

Company Profile

  • Business description

    Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.

  • Contact

    465 North Halstead Street
    Suite 200
    PasadenaCA91107
    USA

    T: +1 626 305-5900

    E: [email protected]

    https://www.xencor.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    260

Stocks News & Analysis

stocks

ASX retail share remains cheap despite weaker earnings

Weaker profit result drives cut to fair value yet shares remain undervalued.
stocks

Lowering profit forecasts on Aussie airlines

The impact of the oil price surge.
stocks

AI isn’t an economic moat killer, but it will disrupt industries

How we’re rethinking companies’ competitive advantages in an AI-first world.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,745.3066.700.77%
CAC 407,830.1886.261.11%
DAX 4022,916.24279.331.23%
Dow JONES (US)46,403.47279.410.61%
FTSE 10010,088.37123.211.24%
HKSE25,335.95272.241.09%
NASDAQ21,924.95163.060.75%
Nikkei 22553,749.621,497.342.87%
NZX 50 Index12,929.30227.551.79%
S&P 5006,590.4434.070.52%
S&P/ASX 2008,534.3045.700.54%
SSE Composite Index3,931.8450.561.30%

Market Movers